Merck & Co., Inc. (MRK) stock forecast and price target
Price $147.76 · data as of November 13, 2026
12-month price target
Gold marker: average target · white marker: today’s price ($147.76)
Analyst ratings
Earnings and revenue estimates
| Period | EPS estimate | EPS growth | Revenue estimate |
|---|---|---|---|
| Current fiscal year ends December 31, 2026 | $2.78 | −69.0% | $67.2B |
| Next fiscal year ends December 31, 2027 | $8.98 | +223.1% | $69.5B |
| Next quarter ends December 31, 2026 | $1.76 | −13.8% | $16.3B |
| Quarter after ends March 31, 2027 | $2.13 | +266.3% | $16.4B |
Consensus of the analysts covering Merck & Co., updated daily. In the last 30 days 19 estimates were raised and 4 lowered.
Our model vs. Wall Street
Analysts see 9.3% upside over 12 months. Our discounted cash flow model with moderate assumptions puts Merck & Co.’s intrinsic value about 31% below today’s market value, and it scores 2.8 out of 5 on our checks. Price targets follow sentiment; a DCF follows cash. When both point the same way the signal is stronger. Try your own assumptions.
Frequently asked questions
What is the Merck & Co. stock price target?
The average 12-month target from 26 analysts is $161.53, 9.3% above the current price of $147.76 Targets range from $105.00 to $186.00.
Is Merck & Co. a buy according to analysts?
The consensus rating is “Buy” (5 strong buy, 14 buy, 9 hold). Ratings are opinions, not guarantees; this is not investment advice.
How much is Merck & Co. expected to earn?
Analysts expect EPS of $2.78 for the fiscal year ending December 31, 2026 and $8.98 the year after.
Analyst consensus estimates and price targets, updated daily. Forecasts can be wrong; this is information, not investment advice.